Free Trial

Douglas Miehm Analyst Performance

Analyst at Royal Bank Of Canada

Douglas Miehm is a stock analyst at Royal Bank Of Canada, covering 11 publicly traded companies across a range of sectors. Over the past year, Douglas Miehm has issued 11 stock ratings, including buy and hold recommendations. While full access to Douglas Miehm's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Douglas Miehm's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
84 Last 10 Years
Buy Recommendations
51.81% 43 Buy Ratings
Companies Covered
11 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy51.8%43 ratings
Hold48.2%40 ratings
Sell0.0%0 ratings

Out of 83 total stock ratings issued by Douglas Miehm at Royal Bank Of Canada, the majority (51.8%) have been Buy recommendations, followed by 48.2% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
63.6% of companies on NASDAQ
7 companies
NYSE
18.2% of companies on NYSE
2 companies
TSE
9.1% of companies on TSE
1 company
OTCMKTS
9.1% of companies on OTCMKTS
1 company

Douglas Miehm, an analyst at Royal Bank Of Canada, currently covers 11 companies listed on NASDAQ, NYSE, TSE and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
10 companies
90.9%
Miscellaneous
1 company
9.1%

Douglas Miehm of Royal Bank Of Canada specializes in stock coverage within the Medical sector, with additional focus on companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
3 companies
27.3%
PHARMACEUTICAL PREPARATIONS
3 companies
27.3%
MED - DRUGS
1 company
9.1%
MED - GENERIC DRG
1 company
9.1%
MEDICAL SERVICES
1 company
9.1%
MEDICAL INSTRUMENTS & SUPPLIES
1 company
9.1%
Miscellaneous
1 company
9.1%

Douglas Miehm's Ratings History at Royal Bank Of Canada

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
MannKind Corporation stock logo
MNKD
MannKind
8/26/2025Boost Price Target$3.95$8.00Outperform
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
8/8/2025Boost Price Target$150.84$185.00Outperform
MannKind Corporation stock logo
MNKD
MannKind
8/7/2025Lower Price Target$3.42$7.00Outperform
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
8/1/2025Boost Price Target$10.01$9.00Outperform
MannKind Corporation stock logo
MNKD
MannKind
7/23/2025Lower Price Target$3.93$8.00Outperform
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
5/2/2025Boost Price Target$5.45$10.00Sector Perform
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
4/4/2025Lower Price Target$12.32$17.00Outperform
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
3/10/2025Lower Price Target$0.66$5.00Outperform
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
2/20/2025Lower Price Target$16.11$18.00Outperform
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
1/30/2025Lower Price Target$7.41$10.00Sector Perform
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
1/29/2025Lower Price Target$17.79$22.00Outperform